TIRmed Pharma´s proprietary compound to treat inflammatory skin disorders was issued patent approval in the US, April 21st, 2020.
TIRmed Pharma receives SME Instrument Phase 1 grant from the European Commission
In Dec, 2019 TIRmed Pharma was awarded an EU-grant for a feasibility study regarding the development of a cream to treat immune responses in atopic dermatitis.